At the 2019 Asembia Specialty Pharmacy Summit, Cardinal Health’s Bruce Feinberg articulates the pros and cons of copay accumulator programs.
Specialty pharmaceuticals make up a huge part of the current drug market, and their impact is only going to grow over the next few years.
How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.
To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2018.
The International Rare Diseases Research Consortium hopes to develop 200 new drugs for rare diseases by 2020, and it seems as if things are better than on track.
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
Some of the most amazing things are happening in the delivery of medical care these days. Surgical techniques, new devices, drugs, and diagnostics can treat and cure many medical conditions.
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Oncology is a complex and rapidly-evolving management challenge for payers.
Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.